Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dinutuximab beta + cisplatin + vincristine + carboplatin + etoposide + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- SIOPEN
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the anti-GD2 monoclonal antibody dinutuximab beta (Qarziba) administered alongside the rapid COJEC induction chemotherapy regimen. Rapid COJEC is a multi-agent chemotherapy protocol comprising cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide. This specific combination is being evaluated in the SIOPEN-Pilot01 Phase Ib clinical trial, sponsored by the Princess Maxima Center for Pediatric Oncology, for the treatment of newly diagnosed high-risk neuroblastoma in pediatric patients. Dinutuximab beta works by binding to the GD2 disialoganglioside on neuroblastoma cells, inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The addition of immunotherapy to standard induction chemotherapy aims to improve outcomes in high-risk patients by targeting residual disease and enhancing the cytotoxic effects of the chemotherapy components.
- Brand names
- Qarziba
- Other names
- dinutuximab beta + rapid COJECDinutuximab Beta with Induction Chemotherapy in High-Risk Neuroblastoma
02
Targets
TOP2A (DNA topoisomerase II)GD2TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on dinutuximab beta + cisplatin + vincristine + carboplatin + etoposide + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dinutuximab beta + cisplatin + vincristine + carboplatin + etoposide + cyclophosphamide.